PT - JOURNAL ARTICLE AU - Michela Antonelli AU - Rose S Penfold AU - Jordi Merino AU - Carole H Sudre AU - Erika Molteni AU - Sarah Berry AU - Liane S Canas AU - Mark S Graham AU - Kerstin Klaser AU - Marc Modat AU - Benjamin Murray AU - Marc F Österdahl AU - Nathan J Cheetham AU - David Drew AU - Long Nguyen AU - Joan Capdeila Pujol AU - Christina Hu AU - Somesh Selvachandran AU - Lorenzo Polidori AU - Anna May AU - Jonathan Wolf AU - Andrew T Chan AU - Alexander Hammers AU - Emma Duncan AU - Tim D Spector AU - Sebastien Ourselin AU - Claire J Steves TI - Post-vaccination SARS-CoV-2 infection: risk factors and illness profile in a prospective, observational community-based case-control study AID - 10.1101/2021.05.24.21257738 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.24.21257738 4099 - http://medrxiv.org/content/early/2021/05/26/2021.05.24.21257738.short 4100 - http://medrxiv.org/content/early/2021/05/26/2021.05.24.21257738.full AB - Background Both BNT162b2 and ChAdOx1 vaccines show good efficacy in clinical trials and real-world data. However, some still contract SARS-CoV-2 post-vaccination. This study identifies risk factors associated with SARS-CoV-2 infection at least 14 days after first vaccination and describes characteristics of post-vaccination illness.Methods Cases were UK adults reporting post-vaccination SARS-CoV-2 infection between 8th December 2020 and 1st May 2021, reporting on the COVID Symptom Study app. We assessed the associations of age, frailty, comorbidity, area-level deprivation and lifestyle factors with infection (vaccinated cases vs. negative-vaccinated controls); and vaccination with illness profile (vaccinated cases vs positive-unvaccinated controls).Findings Post-vaccination infection risk was substantially higher in older adults with frailty (OR= 2.78, 95% CI [1.98-3.89], p-value<0.0001) and in individuals living in most deprived areas (OR vs. intermediate group=1.22, 95%CI [1.04-1.43], p-value=0.01). Risk was lower in individuals with a healthier diet (OR=0.73, 95%CI [0.62-0.86], p-value<0.0001) and without obesity (OR=0.6, 95% CI [0.44-0.82], p-value=0.001). Vaccination was associated with reduced odds of hospitalisation (OR=0.36, 95%CI [0.28-0.46], p-value<0.0001), and high acute-symptom burden (OR=0.51, 95%CI [0.42-0.61], p-value<0.0001). In the 60+ age group, risk of >28 days illness was lower following vaccination (OR=0.72, 95%CI [0.51-1.00], p-value=0.05). Most symptoms were reported less in positive-vaccinated vs. positive-unvaccinated individuals, except sneezing, which was more common post-vaccination (OR=1.24, 95%CI [1.05-1.46], p-value=0.01).Interpretation Our findings highlight reduced symptom burden and duration in those infected post-vaccination. Whilst reassuring, our data should prompt efforts to boost vaccine effectiveness in at-risk populations; moreover, targeted infection control measures will still be appropriate to minimise SARS-CoV-2 infection.Funding This work is supported by UK Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre (BRC) award to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust and via a grant to ZOE Global; the Wellcome Engineering and Physical Sciences Research Council (EPSRC) Centre for Medical Engineering at King’s College London (WT 203148/Z/16/Z). Investigators also received support from the Chronic Disease Research Foundation, the Medical Research Council (MRC), British Heart Foundation, the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, the Wellcome Flagship Programme (WT213038/Z/18/Z and Alzheimer’s Society (AS-JF-17-011), and the Massachusetts Consortium on Pathogen Readiness (MassCPR).Evidence before this study To identify existing evidence for COVID-19 infection post-vaccination, we searched PubMed for peer-reviewed articles published between December 1, 2020 and May 18, 2021 using keywords (“COVID-19” OR “SARS-CoV-2”) AND (“Vaccine” OR “vaccination”) AND (“infection”) AND (“risk factor*” OR “characteristic*”). We did not restrict our search by language or type of publication. Of 202 articles identified, we found no original studies on individual risk and protective factors for COVID-19 infection following vaccination nor on nature and duration of symptoms in vaccinated, community-based individuals. Social and occupational factors influence risk of COVID-19 exposure and infection and personal factors (age, male sex, multiple morbidities and frailty) increased risk for adverse outcomes in COVID-19 in unvaccinated populations. Phase III clinical trials have demonstrated good efficacy of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infection, confirmed in real-world data, which additionally showed reduced risk of adverse outcomes including hospitalisation and death.Added value of this study This is the first observational study investigating characteristics of and factors associated with SARS-CoV-2 infection after COVID-19 vaccination. We found that vaccinated individuals with frailty had higher rates of infection after vaccination than those without. Adverse determinants of health (e.g. increased social deprivation, obesity or unhealthy lifestyle factors such as less healthy diet) were associated with higher likelihood of infection after vaccination. In comparison with unvaccinated individuals, individuals infected after vaccination had fewer symptoms of COVID-19, and more people were entirely asymptomatic. Fewer vaccinated individuals experienced five or more symptoms, required hospitalisation, and, in the older adult group, fewer had prolonged illness duration (symptoms lasting longer than 28 days).Implications of all the available evidence Some individuals still contract COVID-19 after vaccination and our data suggest that frail older adults and those living in more deprived areas are more at risk. However, in most individuals illness appears less severe, with reduced need for hospitalisation and less risk of prolonged illness duration. Our results are relevant for health policy post-vaccination and highlight the need to prioritise those most at risk, whilst also emphasising the balance between the importance of ongoing personal protective measures versus adverse effects from ongoing social restrictions. Strategies such as timely prioritisation of booster vaccination and optimised infection control could be considered for at-risk groups. Research is also needed on how to enhance the immune response to vaccination in those at higher risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunders did not have any role in design, analysis or interpretation of the data. Zoe Global, funded by DHSC, made the app available for data collection as a not-for-profit endeavour.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All app users provided informed consent for use of their data for COVID19 research. In the UK, the app and study were approved by Kings College London (KCL) ethics committee (REMAS no. 18210, review reference LRS-19/20-18210).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study are available to bona fide researchers through UK Health Data Research at https://web.www.healthdatagateway.org/dataset/fddcb382-3051- 4394-8436-b92295f14259/